Canadian Visitors

A contest hosted by BIOTECanada

Join the Canadian delegation at the BIO International Convention and enter to win your registration.

When prompted to enter a registration code, enter "CAN2007" to become eligible to win back your unlimited full conference value pass.

* Use of the "CAN2007" code qualifies all Canadians who have paid for an unlimited full conference value pass to be included in a random selection for full reimbursement.

(Discounted or complimentary unlimited full conference value pass registrations are not eligible).

Canadian Program highlights

Saturday, May 5, 2007
Canadian Kick-Off Event and Briefing
(Open to Canadian Exhibitors and attendees at BIO 2007)
16:00-18:00
Location TBD
Contact: Erin Daily, Consulate General of Canada, Boston
(617) 262-3760, ext. 3353

Sunday, May 6, 2007
Canada - Your Partner in Global Health Innovation
10:45-12:15
BIO 2007 Boston Convention and Exhibition Centre, Room TBD
Contact: Krista Collins, Industry Canada
(613) 941-6479

Gowlings Brunch
11:30-13:30
Fairmont Copley Plaza
Contact: Paul Fortin
paul.fortin@gowlings.com

Canadian Partnering Event at BIO 2007
12:00-17:00
Westin Copley Place Hotel
Contact: Henry Yau, Foreign Affairs and International Trade Canada
(613) 995-6634
henry.yau@international.gc.ca

Monday, May 7, 2007

Canadian Pavilion Opening and Ribbon Cutting
10:30-11:05
BIO 2007 Boston Convention and Exhibition Centre

Venture Capital Networking Event
17:00-18:30
Citi Wang Theatre, Metropolitan Room
Contact: Marie-Louise Hannan, Consulate General of Canada, Boston
617-262-3760 ext. 3365

Soirée Canada (By invitation only)
18:00-21:00
Citi Wang Theatre
Contact: TBD

Tuesday, May 8, 2007

Canada International Seminar
11:00-12:30
Food and Agriculture - Naturally occurring substances and the positive impacts for human health
BIO 2007 Boston Convention and Exhibition Centre, Room TBD

Canada: YourPartner for Global Health Innovation
Track: International Seminars
Sunday, May 06, 2007
10:45 AM - 12:15 PM
Room Number: 254 AB

With its leading-edge R&D andexcellent innovationclimate, Canadahas the second-highest concentration of biotechnology firms in the world, including multinational pharmaceutical companies with global mandates, an excellent network of research-intensive hospitals, universities and government laboratoriesoffering alliance opportunities, and a vibrant contract research industry to support your drug development.

Objectives:

• Highlight researchexcellence from Canada's leading health innovators.
• Offer firsthand accountsof Canada's advantages from firms operating in Canada.
• Explain why Canadareally is a greatplace to invest, partner and grow your life sciences business.

Chair:
Tom Wright, Assistant Deputy Minister, Industry Canada

Speakers:
Maxime Bernier, Minister of Industry, Government of Canada

Paul Lucas, President & CEO, GlaxoSmithKline Canada

Michael Morgan, Chief Science Officer, Genome Canada

Thomas J Hudson, President & Scientific Director, Ontario Institute for Cancer Research

Richard Glickman, Chairman & CEO, Aspreva Pharmaceuticals

Deliver the Promise of Stem Cell Therapeutics?
Track: Bench to Products
Monday, May 07, 2007
9:15 - 10:45 AM
Room Number: 258 B
Currently our ability to control and manipulate stem cells is limited to the manipulation of growth factors while in culture; however, when removed from culture and injected into animals or patients, we lose this control. This session will evaluate the need for greater stem cell control via stem cell engineering in order to create more potent stem cell therapies.

 

Objectives:

• Outline current challenges in commercializing stem cell therapeutics.
• Understand the potential to engineer stem cell products.
• Discuss the regulatory and supply issues that would face engineered stem cell therapeutics.

Chair:
Garheng Kong, Intersouth Partners

Speakers:
Duncan Steward, University of Toronto

Marc Hedrick, President, Cytori Therapeutics

Madhusudan Peshwa, VP Research & Development, MaxCyte, Inc

Biobanks: Building Capacity, Building Understanding, Building Business
Track: Global Health
Monday, May 07, 2007
11:00 AM - 12:30 PM
Room Number: 205 A

Biobanks—large, well-characterized data sets of human population samples—enable biomedical research into the complex diseases that are currently creating a global health crisis, such as asthma, diabetes and heart disease. This session brings together biobanking and bioethics experts from Western Australia, the UK, Estonia, Canada and the United States and introduces the international R&D, business and health-care industries to opportunities in collaborative data harmonization, resource sharing and pharmaceutical investment.

Objectives:

• Outline the potential benefits of international biobanks in the development of biotechnology-based industry, health-care and disease-prevention strategies, pharmaco-epidemiology and -genomics, bioethical frameworks and community engagement in biomedical research.
• Encourage international data harmonization and collaboration on information dissemination and the sharing of expertise and resources in international biobanking and bioethics.
• Outline significant pharmaceutical and other biotechnology/biodiagnostic engagement and investment opportunities in large national biobanks.

Chair:
Lyle J. Palmer, Professor and Foundation Chair in Genetic Epidemiology, Western Australian Institute for Medical Research and The University of Western Australia

Speakers:
Thomas J. Hudson, President and Scientific Director, Ontario Institute for Cancer Research

Arthur L. Caplan, Emanuel & Robert Hart Professor of Bioethics Chair and Director, Center for Bioethics, University of Pennsylvania

Paul Burton, Professor and Chair of Genetic Epidemiology; Scientific Lead - UK Biobank Fosse Way Cohort, University of Leicester

Andres Metspalu, Professor of Biotechnology; Founder and Scientific Advisor - Estonian Genome Project; Treasurer - P3G Public Population Project in Genomics, Institute of Molecular and Cell Biology, Tartu University

Biotech’s Stake in Access and Benefit Sharing (ABS)
Track: Intellectual Property/Legal
Tuesday, May 08, 2007
9:15 - 10:45 AM
Room Number: 257 AB

The biotechnology industry faces unprecedented international pressure to provide mandatory disclosure of the source and origin of genetic resources and related traditional knowledge as a condition for the patentability of its biotechnology inventions as well as provide proof of prior informed consent and benefit sharing. The BIO 2007 panel will analyze the challenges posed by the patent disclosure proposals; explore the latest international developments; and discuss what is being done by the biotech industry to develop positive alternatives to patent-centric ABS enforcement.

Objectives:

• Brief patent counsel on the threat to biotech patentability standards from international adoption of mandatory disclosure of source/origin of genetic resource inventions in important biotech markets in Europe, Asia and elsewhere.
• Raise awareness of need for increased industry advocacy in key capitals and at the multilateral level.
• Outline alternatives outside the patent system to promote equitable benefit sharing from genetic resource inventions with less risk to IP and core industry interests.

Chair:
Jacques J. Gorlin, President, American BioIndustry Alliance

Speakers:
Ananda M. Chakrabarty, Distinguished Professor of Microbiology and Immunology, The University of Illinois at Chicago

Janna C. Tom, Assistant Director, Policy, Analysis and Campus Services, Office of Technology Transfer, University of California, Office of the President

Alan Hesketh, Vice President and General Patent Advisor, Pfizer Inc

Timothy J. Hodges, Director and National Focal Point, Aceess & Benefit Sharing, and Co-Chair, Ad Hoc Open-Ended Working Group on Access and Benefit Sharing, Convention on Biological Diversity, Environment Canada

Naturally Occurring Substances and the Positive Impacts for Human Health
Track: International Seminars
Tuesday, May 08, 2007
11:00 AM - 12:30 PM
Room Number: 253 C

Canadian companies are developing new technologies to transform plant, animal and marine biomass into beneficial health-care products. This panel focuses on Canada’s active, research-oriented industry companies (which include globally recognized food and nutraceutical companies) and research institutions that use technology to develop and enhancevalue-added constituents.

Objectives:

• Share solutions for better health, nutrition, innovative agri-materials and sustainable new food concepts.
• Highlight Canada's high standards for safe and scientifically validated functional foods and nutraceuticals.
• Cultivate relationships and research partnerships in the critical area of foods and biomaterials.

Chair:
Yada Rickey, Professor,Canada Research Chair in Food Protein Structure, Scientific Director Advanced Foods and Materials Network, NCE Department of Food Science, University of Guelph

Speakers:
Barrow Colin, V.P. of Research and Development, Ocean Nutrition Canada

Sirgent Michel, VP Sales, Marketing, Bio-K+ International Inc.

Mascarenhas Lisette J.C., PhD MBA, Ag-West Bio. Inc. - VP Health & Nutrition

Fitzpatrick Kelley C., Director of Health and Nutrition, FLAX CANADA 2015

Risky Business: Risk-Reduced Models for the Biotech Industry
Track: Business Development
Tuesday, May 08, 2007
11:00 AM - 12:30 PM
Room Number: 206 AB

Has the heyday of the fully integrated biopharmaceutical company passed? This panel will discuss the strategic decisions biotech companies make to add value, mitigate risk and bring treatments for life-threatening diseases to patients faster and cheaper than the traditional life sciences company.

Objectives:

• Learn out-of-the box business strategies that biotech companies can pursue to reduce risk for their investors, employees and other stakeholders.
• Learn recent trends in risk-mitigated drug development.
• Learn to manage drug development and marketing with minimal overhead and infrastructure.

Chair:
Robert J. More, Partner, Domain Associates

Speakers:
Scott D. Cormack, President & CEO, OncoGenex Technologies

Theodore Schroeder, President & CEO, Cadence Pharmaceuticals, Inc.

Rajesh Shrotriya, President & CEO, Spectrum Pharmaceuticals

Randall Woods, President & CEO, NovaCardia, Inc.

The Road (and Potholes!) to Commercializing Biotech Animals
Track: Food and Agriculture
Tuesday, May 08, 2007
4:00 - 5:30 PM
Room Number: 253 B

As more biotech animals become available for commercialization, it is critical that prospective marketers be able to navigate the regulatory, intellectual property, public relations and distribution channel obstacles that will undoubtedly stand in their way. This panel will include presentations from the first company to legally commercialize a biotech animal, as well as presentations from several other companies that are extremely close to marketing their own biotech animal products.

Objectives:

• Identify key regulatory, intellectual property, public relations and distribution channel challenges.
• Describe winning strategies for navigating commercialization obstacles and avoiding common mistakes.
• Help prospective marketers understand the broader industry and political dynamics that will affect them.

Chair:
Alan Blake, Chief Executive Officer, Yorktown Technologies, L.P.

Speakers:
John Kelly, Executive Director, MaRS Landing

Mark Walton, President, ViaGen, Inc.

Government of Canada’s website event listings please click her.

For more information, contact info@biotech.ca Subject: 2007 BIO International Convention